Vedolizumab and Malignancy Incidence Vedolizumab and Malignancy Incidence

This study analyzed the long-term incidence of malignancy with vedolizumab, a gut-selective antibody approved to treat moderate-to-severe Crohn ' s disease and ulcerative colitis in adults.Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news